3HP-2827 not checked

3H (Suzhou) Pharmaceuticals Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“3HP-2827 will be administered orally once daily in 28-day cycles.”In the company’s words, NCT06378593 on ClinicalTrials.gov
Tested for
Solid Tumors With FGFR2 Alterations, Adult (2 trials)
Main trialPhase 1/2
“The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations.”In the company’s words, NCT06378593 on ClinicalTrials.gov

Other drugs for Solid Tumors With FGFR2 Alterations, Adult

All 2440 drugs for Solid Tumors With FGFR2 Alterations, Adult

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 16 Jun 2028 A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
Phase 1Not yet recruiting Mar 2028 A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow 3HP-2827

Following is part of Solo: you see every change to 3HP-2827 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in